Abstract
Background. Allogeneic hematopoietic stem cell transplantation (HSCT) is still associated with a high transplant-related mortality rate. In 2009, the EBMT risk score was validated as a simple tool to predict the outcome after allogeneic HSCT for acquired hematological disorders. Objectives. The aim of this study was to validate the applicability of the EBMT risk score for allogeneic HSCT on South Brazilian patients. Methods. A retrospective observational study was performed based on patients' records and data base at Hospital de Clínicas de Porto Alegre, including all allogeneic transplants for malignant and severe aplastic anemia from 1994 to 2010. Patients were categorized according to EBMT risk score and overall survival (OS). Nonrelapse mortality (NRM) and relapse rate (RR) were analyzed. Results. There were 278 evaluable patients. OS, NRM, and RR at five years median followup were 48.7%, 40.7%, and 30.7%, respectively. The OS was 81.8% for risk score 0 and 0% for score 6 (P < 0.001), and NRM was 13.6% and 80% for risk scores 0 and 6, respectively (P = 0.001). Conclusion. The EBMT risk score can be utilized as a tool for clinical decision making before allogeneic HSCT for malignant hematological diseases and severe aplastic anemia at a single center in Brazil.
Highlights
Hematopoietic stem cell transplantation (HSCT) is a potentially curative therapy for a variety of malignant and nonmalignant hematological disorders [1, 2]
Nontransplant treatment strategies [14,15,16,17] have improved in recent years, for chronic myeloid leukemia (CML)
The aim of this study was to validate the applicability of the EBMT risk score for allogeneic hematopoietic stem cell transplantation (HSCT) on South Brazilian patients with acquired hematological disorders from a single center at Hospital de Clınicas de Porto Alegre, Brazil
Summary
Hematopoietic stem cell transplantation (HSCT) is a potentially curative therapy for a variety of malignant and nonmalignant hematological disorders [1, 2]. Allogeneic HSCT remains, associated with a significant risk of morbidity and mortality. This procedure can induce damage of various organs and tissues, from subclinical changes to life-threatening conditions [4, 12, 13], justifying the development of scores for the assessment of HSCT risk in a particular patient. The aim of this study was to validate the applicability of the EBMT risk score for allogeneic HSCT on South Brazilian patients.
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
